Historically, liver biopsy has been used to determine the etiology of liver disease, degree of inflammation, stage of fibrosis, and response to treatment. In the last decade, the advent of non-invasive tests have improved the diagnosis and management of autoimmune liver diseases. For example, serum markers can identify hepatic inflammation, while ultrasound and magnetic resonance imaging can diagnose liver fibrosis. Physicians now have a much larger repertoire of diagnostic tests to assess the liver parenchyma compared to liver biopsy alone. In some rare cases, non-invasive tests may provide an alternative to liver biopsy. In general, however, these non-invasive tests complement liver biopsy and provide quick, accurate, and reliable adjunctive data. 2013; 2:96-103 
Introduction
Autoimmune liver diseases, which include autoimmune hepatitis (AIH), primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC), overlap syndromes, and transplant-related autoimmunity share an immunologic mechanism of disease and pattern of tissue injury. Historically, liver biopsy has been the gold standard for the diagnosis of autoimmune liver diseases; as such, all diagnostic algorithms include histologic findings. A liver biopsy provides information on the etiology of disease, the grade of inflammation, and the stage of fibrosis. Importantly, it can identify compensated cirrhosis in a patient with no other clinical signs of liver disease. This is of great value when determining a screening regimen for hepatocellular carcinoma and esophageal varices.
However, liver biopsy is a flawed gold standard. It is an invasive procedure prone to sampling error with inter-observer variation in interpretation. 1, 2 Sampling of different hepatic lobes shows discordant histological stage a third of the time. 3 In addition, the associated morbidity of liver biopsy is estimated at 3% and mortality at 0.03%. 4 Patients with severe liver damage and coagulopathy are poor biopsy candidates. 5 As we improve our understanding of autoimmune liver diseases, we will continue to develop new serological tests and innovative imaging modalities that both complement and compete with liver biopsy. In this review, we will outline the current data on noninvasive tests in the assessment and management of autoimmune liver diseases ( Table 1) .
Diagnosis of autoimmune liver diseases
The diagnosis of autoimmune liver disease, especially in the setting of overlapping conditions and concomitant illnesses, remains challenging. Early diagnosis and treatment is important for reversing hepatic inflammation and preserving liver function. Due to the clinical heterogeneity of autoimmune liver disease, diagnostic criteria have been devised; the presence of serum autoantibodies is an integral part of making such a diagnosis ( Table 2) . 6 
AIH
Autoimmune hepatitis (AIH) is an immune mediated liver disease characterized by interface hepatitis, increased transaminases, positive autoantibodies, and elevated IgG. 7 Interface hepatitis occurs when cytotoxic T cells cross-react with markers expressed on the surface of hepatocytes. 8 This disease has a prevalence of 10-20/100000 persons and is seen more frequently in women. The peak incidence of disease occurs in the 4 th or 5 th decade of life. 9 The etiology of AIH is uncertain, however, a genetic predisposition plus the loss of self-tolerance unmasks the disease phenotype. The failure of the regulatory immune system may be triggered by previous viral infections or medications. 12 After appropriate therapy of AIH, IgG levels will decrease.
A 2011 study evaluated the test characteristics of autoantibodies in patients with confirmed AIH and patients with liver diseases from alternative etiologies. In that study, the presence of both ANA and SMA had a sensitivity of 43%, a specificity of 99%, and a diagnostic accuracy of 74%; better test characteristics than either marker alone. Also, 51% of patients with AIH had multiple autoantibodies, in comparison to 8% of patients with non-AIH liver disease. 13 Laboratory techniques, sample preparation, and the tissue type can affect the antibody titer.
14 A titer of 1:80 is the lowest non-physiologic positive, however, lower titers may be abnormal in children and young adults. When multiple autoantibodies are present, a lower titer is acceptable for making a diagnosis.
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PBC
Primary biliary cirrhosis (PBC) is characterized by intrahepatic bile duct inflammation, immune mediated destruction of cholangiocytes, and cholestasis. PBC is typically diagnosed based on a congruous set of patient demographics, positive cholestatic markers, and autoimmune serologies. Auto-antigen release may occur following an infectious stimulus (mimic) or hepatocyte apoptosis. 16 The disease occurs almost exclusively in middle-aged females who often present with fatigue and pruritus. Biochemical elevation in alkaline phosphatase is the first laboratory abnormality seen. A positive anti-mitochondrial antibody (AMA) is detected in 95% of patients with the disease. Positive AMA titers can be detected in AIH, acute liver failure, SLE, and rheumatoid arthritis. 17 However, AMA is only detected in 0.5%-1.0% of healthy individuals without PBC. Interestingly, nearly half of patients with PBC will also have a positive ANA and SMA, however, ANA staining will be highly specific for PBCrelated antigens. IgM is elevated in about 70% of those with PBC. The prevalence of PBC is 7-400/million persons and occurs more commonly in Northern European ancestries. 16 Like AIH, the interplay between genetics and environment is important: family history, concomitant autoimmune illnesses, infections, and smoking are all associated with the development of PBC.
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PSC
Primary sclerosing cholangitis (PSC) is a progressive liver disease characterized by autoimmune destruction of both intra-hepatic and extra-hepatic biliary ducts. Bile duct inflammation leads to stricturing, cholestasis, and liver cirrhosis. Various autoantibodies can be detected in patients with PSC, so the serological fingerprint is not easily identified. ANCA, ANA, and SMA are detected in 30%-70% of patients with PSC. Anti-endothelial antibody, anti-cardiolipin, anti-TPO, and rheumatoid factor may also be present, yet sensitivity and specificity of these markers is low. In PSC-overlap syndromes, serology may help diagnose the non-PSC disease process, while imaging with MR cholangiography/ ERCP is most diagnostic of PSC. 19 PSC is more often seen in men and has an association with inflammatory bowel disease, another disease in which serologies like p-ANCA can be detected. Secondary causes of PSC include diseases with increased levels of serum IgG-4 (IgG4-cholangiopathy/IgG4-pancreatopathy). 
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Overlap syndromes
Overlap syndromes share histological, biochemical, serological, and imaging characteristics of AIH, PBC, and PSC. In previous studies, the proportion of people who met criteria for PSC-AIH was 7%-14%, and for people with PBC-AIH was 2%-19%. 21 It is unclear if these overlap conditions constitute a disease spectrum or are distinct diseases themselves, therefore, they remain difficult to diagnose. 22 Studies have looked at the prevalence of autoantibodies in overlap conditions compared to single disease entities. A 2009 study found that ds-DNA was statistically more prevalent in PBC-AIH (60%) compared to PBC (4%) and AIH (26%) alone. PBC-AIH overlap was also more prevalent when ds-DNA was concomitantly detected with AMA. 23 In the future, genome wide association studies may be able to locate genetic haplotypes of each disease, disease subtype, and overlapping conditions. Until then, serum autoantibodies including ANA, AMA, SMA, LKM, ANCA, SLA and immunoglobulin levels are important in diagnosis. 19, 24, 25 Autoimmune liver diseases after transplant Autoimmune liver diseases, as a group, recur in 36%-68% of patients five years after orthotopic liver transplantation. 26 Onethird of patients who are transplanted for PBC will develop recurrent disease. Recurrent PSC occurs in 10%-25% of transplanted livers and recurrent AIH occurs in almost 25% of transplanted livers. Recurrence is now recognized as a major cause of graft dysfunction and failure. 27 Several risk factors for recurrence have been identified and include the type of immunosuppression, the severity of inflammation in the native liver, and HLA subtype (HLA DR 3+ recipient). 28 In recurrent autoimmune liver disease, abnormal biochemical liver tests can fluctuate and lack specificity to diagnose disease recurrence. 29 The same autoantibodies that characterized the original disease are often present in recurrent disease, however, their detection does not necessarily predict recurrence. In a 2003 study, histological abnormalities preceded biochemical abnormalities by 1-5 years. 30 However, the histological features of autoimmune liver disease are often distorted due to the use of immunosuppressant drugs. Recurrent autoimmune hepatitis cannot be diagnosed solely by histological assessment. Clinical and laboratory features must be present that support the diagnosis and exclude other considerations. 31 In addition, de novo autoimmune liver disease occurs in 1%-7% of transplanted livers, more so in children, and is thought to be due to the release of alloantigens from the graft in the setting of immunosuppression. 32 In de novo disease, it is unclear whether immunosuppression unmasks the disease phenotype or if it is really a host versus graft phenomenon. Re-transplant is necessary in 8%-23% of these patients. The complex relationship between ALO antigens and autoantigens in a susceptible host play an important role in this disorder. For de novo autoimmune liver disease, serum autoantibodies and immunoglobulin levels will often be elevated. Risk factors for de novo AIH include HLA status, duration after transplant, and the number of rejection episodes. 31 Other complications after transplant include graft-versus host, chronic rejection, ischemia, and bile duct complications. Therefore, physicians must use a variety of techniques including laboratory tests, imaging, and biopsy to determine the etiology of graft dysfunction. The detection of serum autoantibodies and immunoglobulin levels in these conditions provides non-invasive diagnostic information to improve outcomes after transplant.
Novel serum antibodies for the diagnosis of autoimmune liver disease
As laboratory techniques like radioimmunoassays and ELISA improve and become more prevalent, newer autoantibodies are being identified that can help diagnose autoimmune liver diseases. In addition, genetic testing has found that disease presentation and prognosis may be dependent on an individual's set of HLA haplotypes. 33 This opens up an exciting possibility for improved non-invasive techniques for diagnosis and personalized treatment regimens ( Table 2) .
Soluble liver antigen (SLA) is a very specific marker of AIH and is found in 11%-22% of people with type I AIH and 18%-44% of children with type II AIH. SLA has a diagnostic specificity of 99% for AIH. 34 The presence of SLA has been associated with more severe histological changes, higher relapse, longer immunosuppression courses, and increased rates of transplant and death. 35 This is the most promising new serological marker and it has been incorporated into the simplified AIH diagnostic criteria. 36 Also, the immunomorphology of SMA has been elucidated and found to contain filamentous actin, or F-actin. A staining pattern that detects F-actin has been found to have a sensitivity of 71% and a specificity of 90%, which are better test characteristics than SMA alone. 37 The prognostic capability of F-actin, however, is largely unknown. Antibodies to liver cytosol type I (LC1) have been associated with concomitant autoimmune diseases and rapid progression of AIH. 38 Antibodies to asialoglycoprotein receptor is present in 67%-88% of those with AIH, compared to much less detection in those with viral hepatitis, alcoholic liver disease, and PBC. 39 Anti-ribosomal P protein, which is commonly present in systemic lupus, has been isolated in patients with AIH in the absence of lupus and predicts a poorer prognosis. 40 This is also true for the detection of anti-chromatin antibodies and antidsDNA. 41 Lastly, anti-cyclic citrullinated peptide (anti-CCP) is highly specific for erosive rheumatoid arthritis (RA), however, it is also found in 9%-11% of patients with AIH, commonly in the absence of RA. These patients have a propensity to develop liver failure and cirrhosis. 42 Subtype antinuclear antibodies have been discovered that may help diagnose PBC in the absence of AMA. Twenty-seven percent of patients with PBC have anti-Sp100; 16%-25% have anti-gp210; and 16% have anti-centromere. 43 It is hypothesized that there is an antigenic nuclear complex that when disrupted may lead to the disease phenotype. 44 Adding these nuclear markers to the well-established cytoplasmic marker AMA facilitates the diagnosis if PBC. The prognostic indication of these various autoantibodies is still being established.
In AIH of a transplanted liver, a novel serum autoantibody, GSTT1, is elevated in the setting of severe centri-lobular necrosis.
This marker is often seen in addition to the typical markers of AIH, however, it may be present alone. This protein target has been identified as a glutathione transferase, and it is absent in about 20% of the population. It is speculated, therefore, that de novo autoimmunity may be an anti-graft response. 45 The discovery of these novel markers can help diagnose autoimmune liver disease and provide prognostic information. At this time, the availability and standardization of these assays is lacking.
14 In addition, it is unclear how the disappearance and reappearance of certain autoantibodies affects outcome. 46 These antibodies have a low negative predictive value of a poor outcome. 47 Still, it is likely that commercial assays will soon become available to provide serological support for the clinician. In addition, the antibody fingerprint may reveal newer treatment targets. 48 As we understand the disease mechanism further, we will improve our current knowledge base and discover additional autoantibodies. As a battery of autoantibodies becomes available, the utility of obtaining a liver biopsy for diagnostic purposes decreases. 34 However, antibody titers correlate poorly with disease severity, degree of liver inflammation, and response to treatment. 47 This was demonstrated in a 2009 study, where antibody status did not predict AIH activity or outcome. Liver histology is needed to determine initial severity of disease as well as response to treatment. 49 In addition, overlap syndromes remain difficult to diagnose without biopsy. Knowing the predominant histology as well as any additional processes, like ductopenia, may help guide treatment. Patients may be hesitant to start a long course of immunosuppression without having the data from a liver biopsy. In addition, autoantibodies may be altered by concomitant autoimmune illness. Currently, physicians use liver histology to determine the duration of steroid taper and whether to replace with a steroid sparing immunosuppressant. 5 But will non-invasive imaging techniques supplant our reliance on liver biopsy?
Non-invasive imaging modalities to predict liver fibrosis in autoimmune liver disease
The culmination of all autoimmune liver diseases is liver fibrosis, and the assessment of liver fibrosis is an important tool in identifying the severity of autoimmune liver diseases. The gold standard for detecting hepatic fibrosis is liver biopsy. However, liver biopsy is an invasive method that is costly, has inherent risks, and is limited by sampling bias. In short, liver biopsy is an imperfect gold standard.
Research has focused on non-invasive measurements of liver fibrosis. In a 1995 publication in Science, magnetic resonance imaging (MRI) was able to detect low level particle displacement patterns. 50 In addition, liver stiffness values measured with MRI showed a linear correlation with the degree of liver fibrosis. 51 These findings confirmed that MRI is a feasible modality for detecting the elasticity and other mechanical properties of tissue. Since then, MRI, as well as transient elastography (TE) and serum marker panels, have been applied to the non-invasive detection of liver fibrosis.
MRI techniques that have been used to detect liver fibrosis include MR elastography (MRE), diffusion weighted imaging (DWI), perfusion weighted imaging (PWI), and MR spectroscopy. 52 MRE and DWI have been used most commonly in a large number of clinical trials including in patients with autoimmune liver disease. In a 2012 meta-analysis comparing the accuracy of MRE versus DWI, MRE was found to be diagnostically superior with a sensitivity of 94%, a specificity of 95%, OR of 20, and ROC of 98%. It performed better than DWI in detecting early, intermediate, and advanced fibrosis. 53, 54 In addition, it is independent of body habitus and operator characteristics. 55 In AIH, early fibrosis has been shown to be reversible with aggressive treatment. In late fibrosis, physicians need to screen patients for complications of portal hypertension and prepare the patient for transplantation. Therefore, MRI imaging may help diagnose disease and also guide treatment. Currently, combined MRI and MRE abdominal protocols are being used to perform a parenchymal evaluation of the liver (eg exclude HCC), to identify the degree of liver fibrosis (eg liver stiffness on MRE), and to look for features of portal hypertension. This is an accurate test that is unique in its ability to globally assess the liver for space occupying lesions and liver fibrosis; while also removing the sampling error that can be seen with liver biopsy and transient elastography. The MRI protocols, however, can be long and cumbersome. More focused studies are needed in patients with autoimmune liver disease.
Transient elastography (TE, Fibroscan) is an ultrasound technique that uses elastic shear wave technology to measure liver stiffness (in kPa). The transducer probe is placed in the intercostal space adjacent to the right lobe of the liver and multiple readings can be easily recorded. 56 TE is an emerging modality in detecting liver fibrosis and may also be able to predict the downstream consequences of portal hypertension. A stiffness reading < 6 kPa is normal and a reading above 12 kPa indicates cirrhosis, with varying degrees of liver fibrosis with values in between. This technique is rapid, reproducible, and operator friendly, thus, making it a popular choice for the assessment of liver fibrosis in the doctors' office.
A 2008 meta-analysis looked at the test characteristics of TE from 50 studies. TE performed best at differentiating cirrhosis versus no cirrhosis, with an adjusted AUROC of 99%. The adjusted AUROC for detecting F2 fibrosis was 91%. F2 staging is important to detect because, with treatment, fibrosis may be abated. The heterogeneity of this measurement improved when the etiology of the underlying liver disease was taken into account. 57 In a PBC cohort, TE was determined to be one of the best surrogate markers of liver fibrosis. In a 2012 study, TE was used to determine performance standards in 150 patients with PBC. TE was able to delineate mild fibrosis from advanced fibrosis. In addition, longitudinal measurements were performed that showed that liver stiffness is stable in non-cirrhotic patients treated with ursodeoxycholic acid, however, those patients with F4 cirrhosis had an 8-fold increase in decompensated disease, transplant, or death. 58 Without liver biopsy, these clinicians were able to predict progression of liver stiffness and correlate this with a poor outcome. Similar results were ascertained in a PSC cohort, as TE was correlated to both histologic and fibrosis stages. 59 In AIH, however, the accuracy of TE may not be so clear. The hallmark of AIH is dense, peri-portal lymphocytic aggregates. A case report documents a patient with AIH who had an initial TE reading of 21 kPa, a biopsy that showed inflammation but minimal fibrosis, and a repeat TE reading 12 months after treatment of 4 kPa. Another case report talks about a patient with AIH who had bridging fibrosis on initial biopsy, a TE that was consistent with F4 cirrhosis, but had regression of her fibrosis after treatment. 60 In these cases, TE may give disproportionately high results in strongly inflammatory conditions, like AIH or acute viral hepatitis. 61 In addition, fibrosis is a fluid process that may require repeat evaluations.
In general, TE has excellent reproducibility and reliability, however, a large prospective study found both patient and operator characteristics that correlated with measurement failure. In the study, liver stiffness measurements failed in about 1 out of 5 cases. The most significant reasons for failure were obesity, increased waist circumference, narrow intercostal space, hepatic inflammation/steatosis, and operator experience. 62 The presence of ascites, biliary obstruction, and cardiac failure also affects accuracy. 63 TE performs best when differentiating mild fibrosis (F0/ F1) from cirrhosis (F4). It was more sensitive in PBC/PSC than AIH, in which a robust immunological response causes hepatic inflammation and ALT and AST are often >200 IU/L. In these patients, serum fibrosis markers (eg hepascore, fibrotest, fibrosure, ELF) and a quality liver biopsy (>1.5 cm) are good alternatives. Therefore, a clinician needs to evaluate the appropriateness of each non-invasive and invasive test required to make the most accurate diagnosis.
Serum biochemical panels and autoimmune liver disease
The ability to use clinical acumen to identify those with cirrhosis remains a challenge. In addition, the test characteristics for making a clinical diagnosis of liver cirrhosis have not been well studied.
In a meta-analysis, the diagnosis of cirrhosis was more likely in patients with ascites (LR 7.2), platelets <160000 (LR 6.3), and spider nevi (LR 4.3). 64 The overall impression of the physician was less accurate than the above physical and biochemical findings. A variety of serum biochemical panels (APRI, Hepascore, and hyaluronic acid) have been developed to assist the clinician in making this diagnosis.
Aspartate aminotransferase-to-platelet ratio index (APRI) is a widely available and non-invasive calculation. The Hepascore is computed based on age, sex, and serum levels of total bilirubin, gamma-glutamyl transferase, alpha-2-microglobulin, and hyaluronic acid. Hyaluronic acid is a component of the extracellular matrix that gets deposited during fibrous deposition after liver injury. 65 All of these tests have been most studied in detecting cirrhosis in Hepatitis C patients. There are very few studies looking at serum panels in autoimmune liver diseases. One study compared TE versus non-invasive markers (including APRI) in PBC. The study determined that TE was a simple way to determine histologic stage; the addition of serum markers failed to improve the AUROC. 66 A 2010 study showed that laboratory tests had a 94% accuracy in detecting frank cirrhosis, but lagged far behind non-invasive techniques in determining the degree of fibrosis. The most relevant study was performed by Malik et al, which looked at 404 patients with a variety of liver diseases including viral, metabolic, and autoimmune. 124 of the patients had compensated cirrhosis. The diagnostic accuracy of transient elastography, clinical signs, Hepascore, APRI, and hyaluronic acid were compared. The reference standard was liver biopsy. TE was diagnostically superior to clinical evaluation, Hepascore, APRI, and hyaluronic acid. This difference remained after subgroup analysis. They concluded that when these tests are used in a complementary fashion, histologic grading is likely accurate and can guide treatment and prognosis.
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Future directions: will liver biopsy become obsolete?
The liver biopsy is a tool with inherent bias making it an imperfect reference standard for the diagnosis of autoimmune liver disease. While non-invasive modalities are available, they are currently unable to provide enough details on the etiology of liver disease and the grade of inflammation to supplant liver biopsy. Hence, these tests are currently being used in a complementary fashion ( Table 3) . A clinician must calculate the test characteristics for each individual patient and find a combination of studies that can provide a timely diagnosis and severity of disease. Ideally, the most appropriate tests should also be minimally invasive and cost effective. In the future, technological advances of non-invasive imaging and serological tests will make liver biopsy a less essential, diagnostic option. Until then, liver biopsy is a fundamental tool in the diagnosis, staging, and management of autoimmune liver disease and its use is recommended until superior methods are fully validated.
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